Clinical Trial Update: Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical study evaluated combining bortezomib with CHOP chemotherapy in patients with advanced aggressive T-cell lymphomas and NK/T-cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer T-cell Lymphoma
• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Vincristine (vincristine)

Snippet

Sponsor: Samsung Medical Center | Conditions: Peripheral T-Cell Lymphomas, Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED